Century Therapeutics will present at the Piper Sandler Healthcare Conference on December 4, highlighting advances in iPSC cell therapies.
Quiver AI Summary
Century Therapeutics, a biotechnology company specializing in induced pluripotent stem cell (iPSC) therapies for immuno-oncology and autoimmune diseases, announced its participation in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. CEO Brent Pfeiffenberger and Chief Scientific Officer Chad Cowan will present in a fireside chat and participate in a panel discussion focused on autoimmune disease cell therapy. A live broadcast of the fireside chat will be available on the company's website, with a replay accessible for 90 days. Century Therapeutics aims to develop innovative cell therapies that target various cancers and autoimmune conditions, leveraging their expertise to overcome limitations of traditional cell therapies and expand patient access.
Potential Positives
- Participation in prominent industry events, such as the Piper Sandler Healthcare Conference, enhances the company's visibility and credibility in the biotechnology sector.
- Presentation by key executives and the Chief Scientific Officer underscores the company's leadership and expertise in developing innovative cell therapies for cancer and autoimmune diseases.
- Live webcast of the events increases accessibility for investors and stakeholders, promoting transparency and engagement with the company’s strategic initiatives.
Potential Negatives
- The press release focuses heavily on upcoming presentations without delivering any new significant information about product developments or company milestones, which may raise concerns about the lack of progress or updates on their pipeline.
FAQ
What events will Century Therapeutics participate in at the Piper Sandler Conference?
Century Therapeutics will participate in a panel on Autoimmune Disease Cell Therapy and a fireside chat on December 4, 2024.
Who are the presenters at the Piper Sandler Conference?
Presenters include Chad Cowan, Ph.D. (Chief Scientific Officer) and Brent Pfeiffenberger, Pharm.D. (Chief Executive Officer).
How can I access the live webcast of the fireside chat?
The live webcast can be accessed on the “Events & Presentations” page of the investor section on Century Therapeutics’ website.
What is the focus of Century Therapeutics?
Century Therapeutics focuses on developing iPSC-derived cell therapies for cancer and autoimmune diseases to improve patient access and treatment efficacy.
Where can I find more information about Century Therapeutics?
More information about Century Therapeutics can be found on their official website at www.centurytx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IPSC Insider Trading Activity
$IPSC insiders have traded $IPSC stock on the open market 10 times in the past 6 months. Of those trades, 1 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $IPSC stock by insiders over the last 6 months:
- ADRIENNE FARID (Chief Operations Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 2,106 shares.
- DOUGLAS CARR (SVP Finance & Operations) has traded it 2 times. They made 0 purchases and 2 sales, selling 572 shares.
- DAPHNE QUIMI purchased 5,000 shares.
- GREGORY RUSSOTTI (See Remarks) has traded it 5 times. They made 0 purchases and 5 sales, selling 12,386 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IPSC Hedge Fund Activity
We have seen 32 institutional investors add shares of $IPSC stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 2,040,609 shares (+892.6%) to their portfolio in Q3 2024
- AVIDITY PARTNERS MANAGEMENT LP removed 1,221,555 shares (-100.0%) from their portfolio in Q2 2024
- BOXER CAPITAL, LLC removed 1,001,603 shares (-20.4%) from their portfolio in Q3 2024
- VANGUARD GROUP INC added 743,082 shares (+42.9%) to their portfolio in Q3 2024
- OCTAGON CAPITAL ADVISORS LP removed 666,825 shares (-50.0%) from their portfolio in Q3 2024
- FMR LLC removed 428,768 shares (-14.5%) from their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC added 322,700 shares (+195.0%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:
-
Autoimmune Disease Cell Therapy Panel:
3:00 PM ET
- Presenter: Chad Cowan, Ph.D., Chief Scientific Officer
-
Fireside Chat:
4:30 PM ET
- Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer
A live webcast of the fireside chat can be accessed on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations . A replay of the webcast will be available for 90 days following the event.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit www.centurytx.com .
For More Information:
Investor Relations & Media Contacts
Century Therapeutics
Katja Buhrer
SVP, Head of Corporate Affairs and Strategy
[email protected]
917-969-3438
Argot Partners
Noor Pahlavi
[email protected]
212-600-1902
